Treatment of experimental cryptococcosis with SCH 39304 and fluconazole.
AUTOR(ES)
Negroni, R
RESUMO
The efficacy of two triazoles, SCH 39304 and fluconazole, in the treatment of disseminated cryptococcosis in Wistar rats was determined. A total of 160 rats were inoculated intracardiacally with 2 x 10(5) cells of Cryptococcus neoformans. Both drugs were administered by gavage once daily, at three doses (8, 16, and 32 mg/kg/day). Two treatment schedules were followed: (i) treatment began 1 week after infection and continued for 3 weeks and (ii) prophylaxis treatment began 3 days before infection and continued an additional 3 weeks. Evaluation was based on (i) macroscopic examination of lungs, (ii) microscopic examination of brains and lungs, (iii) histopathology of brains and lungs, and (iv) determination of number of CFU in brains. The number of CFU was the best measure of activity. SCH 39304 was more active than fluconazole in both regimens, and, prophylactically, SCH 39304 was able to achieve biological cures.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=245190Documentos Relacionados
- Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304.
- Efficacy of SCH39304 in murine cryptococcosis.
- Cavitating pulmonary cryptococcosis developing in an HIV antibody patient despite prior treatment with fluconazole.
- Comparison of SCH 39304, fluconazole, and ketoconazole for treatment of systemic infections in mice.
- Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis.
